As PP2Ac constitutes the catalytic subunit of the most important Tau-phosphatase, inhibition of its degradation trigger, namely the MID1-α4 complex, offers promising possibilities to find novel treatment options for AD. The gene discussed is APP; the disease is Alzheimer disease.